Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $37.20

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received a consensus rating of "Moderate Buy" from the eighteen analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $37.20.

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. B. Riley reissued a "buy" rating and set a $35.00 price objective (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Bank of America cut their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Robert W. Baird assumed coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective for the company.

Insider Activity

In other Denali Therapeutics news, insider Carole Ho sold 12,255 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Vicki L. Sato sold 3,080 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now directly owns 107,976 shares in the company, valued at $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is currently owned by company insiders.

Remove Ads

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its stake in shares of Denali Therapeutics by 163.7% in the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock worth $1,162,000 after acquiring an additional 24,767 shares during the period. FMR LLC raised its holdings in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after purchasing an additional 7,596,508 shares in the last quarter. Algert Global LLC lifted its position in Denali Therapeutics by 82.4% in the third quarter. Algert Global LLC now owns 48,630 shares of the company's stock worth $1,417,000 after purchasing an additional 21,975 shares during the period. Proficio Capital Partners LLC bought a new position in Denali Therapeutics during the 4th quarter valued at $514,000. Finally, JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after purchasing an additional 14,324 shares during the period. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Trading Up 4.1 %

NASDAQ:DNLI traded up $0.58 on Wednesday, reaching $14.78. The stock had a trading volume of 1,513,530 shares, compared to its average volume of 1,024,755. The company has a 50-day moving average of $19.05 and a 200 day moving average of $23.23. The stock has a market cap of $2.15 billion, a P/E ratio of -5.36 and a beta of 1.46. Denali Therapeutics has a 12-month low of $13.67 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. On average, equities analysts predict that Denali Therapeutics will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.